Humacyte Shares Under Pressure as Revenue Miss Sparks Analyst Downgrade

Humacyte's Q4 revenue fell short, driven by a sharp price cut for its Symvess product. The stock plunged to a 52-week low after BTIG halved its price target.

A significant revenue shortfall and pricing pressures for its flagship product have triggered a sharp reassessment of Humacyte's near-term prospects. The biotechnology firm's latest quarterly results fell well below market expectations, prompting immediate analyst reaction and sending its stock to a fresh low.

Quarterly Performance Misses the Mark

For the fourth quarter, Humacyte reported revenue of approximately $0.5 million, a figure that came in substantially under the consensus estimate of $1.35 million. A key factor behind this underperformance was a notable reduction in the selling price for its bioadaptive vascular product, Symvess. The price per unit dropped to around $17,000, down from a previous level of $24,500. Across the entire 2025 fiscal year, the company shipped a total of 61 units.

The net loss for the quarter expanded to $24.8 million, compared to a loss of $20.9 million in the same period the prior year. As of year-end, Humacyte's cash and equivalents stood at $50.5 million.

Immediate Market and Analyst Reaction

In response to the weak figures, investment bank BTIG slashed its price target for Humacyte stock by 50%, moving it from $6.00 to $3.00. Despite this drastic reduction, the firm maintained its "buy" rating on the shares, though it cited increased pressure from both pricing dynamics and shifting sales volumes.

Investors delivered their own verdict, with the stock plunging over 13% on Friday. This sell-off drove the share price to a new 52-week low of $0.68.

Future Catalysts and Strategic Moves

Attention now turns to future milestones. Management is focusing on June 2026, when top-line results from the pivotal V012 Phase 3 clinical trial are expected. The data from this study on the company's bioengineered human acellular vessels (HAVs) are viewed as a critical driver for the regulatory pathway forward.

Concurrently, the company is advancing its international expansion strategy, having recently submitted a regulatory application in Israel. Humacyte has also secured funding commitments from the U.S. Department of Defense for the procurement of its vascular technology. The next quarterly update is scheduled for release on May 7, 2026.